Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.
July 27, 2023 | 8:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma, maintaining a price target of $23. This could potentially boost investor confidence in the stock.
Analyst ratings often influence investor sentiment. A reiterated 'Buy' rating indicates that the analyst continues to have confidence in the company's prospects. This could potentially lead to increased demand for the stock, pushing the price upwards in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100